Thursday March 21, 2019
Home Entertainment Bollywood joi...

Bollywood joins hands against breast cancer, urges people to pay attention

0
//
Breast Cancer
Bollywood joins hands against breast cancer, urges people to pay attention

New Delhi, Oct 5 : Some of the Bollywood celebrities including Aditi Rao Hydari, Arjun Kapoor, Ali Fazal came together to organically lend their support to an initiative titled #PayAttention, that urges women to take up breast self-examination.

Avon, the women’s beauty brand bringing new dimensions to beauty, launched #PayAttention on September 7 and now many Bollywood celebrities are urging people to pay attention.

Aditi Rao Hydari, Brand Ambassador, Avon India: I have always believed in the brand ethos of “Beauty with a Purpose” and for me beauty always has a purpose in terms of saving lives and making a difference. With this initiative, we urge women and men to spend a few minutes to #PayAttention to themselves through a breast self-examination.

“With knowledge, we can win the battle against Breast Cancer. Few minutes every month can help you detect early symptoms and early detection is early cure.”

Arjun Kapoor: It is a fantastic initiative and I will like to help in any way possible.”

Ashwiny Iyer Tiwari, director of “Bariely ki Barfi”: In the past two years, two of my friends were diagnosed with breast cancer. With their strong willpower, they overcome this disease and their life has completely changed after the diagnosis. I believe it can happen to anyone, even young women.”

Kriti Sanon: It is absolutely true that breast cancer can happen at a young age too. I am glad Avon India has initiated this drive for awareness

Kiara Advani: Awareness is the Key! Let’s spread the word ladies. A breast self-exam can save your life!”

Mini Mathur: Don’t wait to discover breast cancer when you’re ‘old’. Girls be aware it can strike you in teenage as well. Please resist it with checkups.

The campaign has unified more than 100 million people to give voice to a larger purpose – save million lives through early detection using a breast self-examination.(IANS)

Next Story

Common Diabetes Drug May Offer Treatment For Breast Cancer, Says Study

However, neither of the drugs were originally designed to treat cancer

0
Cancer
Cancer Ribbon. Pixabay
Repurposing a common diabetes drug as well as another used for treating a group of inherited and acquired disorders may also help in the fight against resistant breast cancers that currently have no targeted therapy, finds a study.
The study, led by the University of Chicago, showed that the two existing drugs named metformin and haemin suppress tumour growth in mice, Xinhua reported.
“This is the first joint use of these two drugs. We think we have elucidated a new mechanism, something basic and fundamental, and found ways to use it,” said Marsha Rosner, Professor at the varsity.
The researchers found that the primary anti-cancer target for haemin is a transcription factor known as BACH1 (BTB and CNC homology1). This protein is often highly expressed in triple negative breast cancers and is required for metastasis.
BACH1 targets mitochondrial metabolism and can suppress a key source of cellular energy. When BACH1 is high, this energy source is shut down, the report said.
However, when cancer cells were treated with haemin, BACH1 was reduced, causing BACH1-depleted cancer cells to change metabolic pathways. This caused cancers that are vulnerable to metformin to suppress mitochondrial respiration.
Diabetes
Representational image. Pixabay
“We found that this novel combination, haemin plus metformin, can suppress tumour growth, and we validated this in mouse tumour models,” explained Jiyoung Lee from the varsity.
The findings can extend beyond breast cancer.
BACH1 expression is enriched not only in triple negative breast cancers, but is also seen in many other cancers including lung, kidney, uterus, prostate and acute myeloid leukemia, the researchers noted.
However, neither of the drugs were originally designed to treat cancer.
Metformin, discovered in 1922 and used clinically since 1957, was developed to treat Type-2 diabetes. It decreases glucose production by the liver and increases insulin sensitivity.
Haemin, marketed as panhematin, was first crystallised from blood in 1853. It is now used to treat defects of haemin synthesis. These defects can cause porphyrias, a group of inherited and acquired disorders. (IANS)